New chemical modification reduces off-target effects in siRNA drugs

Small interfering RNA (siRNA) drugs are a class of therapeutic agents that silence specific genes associated with inherited diseases.

Omalizumab Superior to Oral Immunotherapy for Kids With Multi-Food Allergy

SAN DIEGO — Omalizumab (Xolair) injections outperformed oral immunotherapy (OIT) in increasing tolerance among children with multi-food allergy, largely because many patients couldn’t tolerate OIT,

March 5, 2025

Cooperation between relyon plasma GmbH and Viromed Medical GmbH – Biotech Investments

EQS-News: Viromed Medical AG / Key word(s): Alliance Viromed Medical AG: Cooperation between relyon plasma GmbH and Viromed Medical GmbH 05.12.2024 / 12:10 CET/CEST The

December 6, 2024

Ginkgo Bioworks handed a DARPA manufacturing contract; Merck hits a primary endpoint for Keytruda in first-line cervical cancer

The Defense Advanced Research Projects Agency (DARPA) is giving Ginkgo Bioworks a 4-year contract worth up to $18 million, to manufacture complex therapeutic proteins. Ginkgo

July 20, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.